KDR and neoplasm: As a representative of tyrosine kinase inhibitors, the main mechanism underlying tumor angiogenesis suppression by sorafenib involves inhibition of vascular endothelial growth factor (VEGF), vascular Endothelial Growth Factor Receptor (VEGFR), and platelet derived growth factor (PDGF).